NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Forecast & News

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its quarterly earnings data on Thursday, November, 7th. The company reported $0.10 EPS for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.02. The business had revenue of $80.14 million for the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The firm's revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Amphastar Pharmaceuticals.

3 brokers have issued 1 year price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $22.20 to $29.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $24.73 in the next twelve months. This suggests a possible upside of 23.7% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amphastar Pharmaceuticals.

Headlines about AMPH stock have been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 2,700,000 shares, a decline of 5.6% from the December 15th total of 2,860,000 shares. Based on an average daily trading volume, of 223,000 shares, the short-interest ratio is currently 12.1 days. Approximately 7.6% of the company's stock are sold short. View Amphastar Pharmaceuticals' Current Options Chain.

Some companies that are related to Amphastar Pharmaceuticals include FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Axsome Therapeutics (AXSM), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Uniqure (QURE) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), AbbVie (ABBV), Advanced Micro Devices (AMD), Cellectis (CLLS), Clovis Oncology (CLVS) and Neurocrine Biosciences (NBIX).

Amphastar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Nisa Investment Advisors LLC (0.06%), State of Alaska Department of Revenue (0.06%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Jack Y Zhang, Jason B Shandell, Richard K Prins, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $20.00.

Amphastar Pharmaceuticals has a market capitalization of $938.80 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.

The official website for Amphastar Pharmaceuticals is http://www.amphastar.com/.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]